Mercy BioAnalytics
Natick
About Mercy BioAnalytics
Mercy BioAnalytics is a biotechnology company that aims to improve and save the lives of people through the early detection of cancer. It has developed a process that uses nano-particles that are extraordinarily abundant in blood and carry information about their parent cell – known as extracellular vesicles, or EVs – to detect stage I cancer. Paul Blavin and Joseph Sedlak founded the Natick, Massachusetts-based company in 2018.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $127.3M
- Funding stage: Early Stage Venture
- Last round: Series B (Sep 2025)
- Website: mercybio.com
- Phone: 480-540-5566
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/mercy-bioanalytics-39676 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.